Bortezomib Targets Sp Transcription Factors in Cancer Cells.

Karki Ket al. Mol Pharmacol. 2018 Oct. doi: 10.1124/mol.118.112797. [Epub 2018 Aug 16]

IRF4 in multiple myeloma-Biology, disease and therapeutic target.

Agnarelli A et al. Leuk Res. 2018 Sep. doi: 10.1016/j.leukres.2018.07.025. [Epub 2018 Aug 3]

PGC1β regulates multiple myeloma tumor growth through LDHA-mediated glycolytic metabolism.

Zhang H et al. Mol Oncol. 2018 Sep. doi: 10.1002/1878-0261.12363. [Epub 2018 Aug 14]

Potent Activity of the Bromodomain Inhibitor OTX015 in Multiple Myeloma.

Shi J et al. Mol Pharm. 2018 Sep 4. doi: 10.1021/acs.molpharmaceut.8b00554. [Epub 2018 Aug 9]

High chymotrypsin-like activity in the plasma of patients with newly diagnosed multiple myeloma treated with bortezomib is predictive of a better response and longer PFS.

Romaniuk Wet al. Ann Hematol. 2018 Oct. doi: 10.1007/s00277-018-3393-7. [Epub 2018 Jun 26]

Simvastatin reverses multiple myeloma serum-induced prothrombotic phenotype in endothelial cells via ERK 1/2 signalling pathway.

Dong R et al. Blood Coagul Fibrinolysis. 2018 Sep. doi: 10.1097/MBC.0000000000000745.

Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies.

Peled A et al. Cytokine. 2018 Sep. doi: 10.1016/j.cyto.2018.02.020.

Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model.

Kim C et al. Cancer Lett. 2018 Sep 1. doi: 10.1016/j.canlet.2018.05.038. [Epub 2018 May 29]

Co-inhibition of BET and proteasome enhances ER stress and Bim-dependent apoptosis with augmented cancer therapeutic efficacy.

Qian G et al. Cancer Lett. 2018 Oct 28. doi: 10.1016/j.canlet.2018.07.033. [Epub 2018 Jul 29]

Nanobody-based dual epitopes protein identification (DepID) assay for measuring soluble CD38 in plasma of multiple myeloma patients.

Li T et al. Anal Chim Acta. 2018 Oct 31. doi: 10.1016/j.aca.2018.04.061. [Epub 2018 Apr 26]

Biomarkers for checkpoint inhibition in hematologic malignancies.

Atanackovic D. and Luetkens T. Semin Cancer Biol. 2018 Oct. doi: 10.1016/j.semcancer.2018.05.005. [Epub 2018 Jun 18]

Antiproliferation activities of NK4 on multiple myeloma.

Que Wet al. Exp Ther Med. 2018 Oc. doi: 10.3892/etm.2018.6649. [Epub 2018 Aug 22]

Effects of microRNA‑125b on multiple myeloma cell growth in vitro and in vivo.

Jiang Y et al. Oncol Rep. 2018 Nov. doi: 10.3892/or.2018.6668. [Epub 2018 Aug 23]

Pterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cells.

Mei H et al. Int J Mol Med. 2018 Nov. doi: 10.3892/ijmm.2018.3857. [Epub 2018 Sep 5]

Serum miR-30d as a novel biomarker for multiple myeloma and its antitumor role in U266 cells through the targeting of the MTDH/PI3K/Akt signaling pathway.

Zhu B et al. Int J Oncol. 2018 Nov. doi: 10.3892/ijo.2018.4532. [Epub 2018 Aug 21]

Identification of a novel c-Myc inhibitor with antitumor effects on multiple myeloma cells.

Yao Ret al. Biosci Rep. 2018 Sep 19. doi: 10.1042/BSR20181027.